NBIX · ISSUER CIK 914475
NEUROCRINE BIOSCIENCES INC
Between Aug 1, 2026 and Oct 29, 2026, 11 NEUROCRINE BIOSCIENCES INC insiders reported $0.00 of open-market purchases and $826K of sales on SEC Form 4.
↗11 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 3 of 3 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$826KInsider selling
−$826KNet open-market
Sep 15, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 15, 202617:07 | Sep 11, 2026 | NBIX | Chief Scientific Officer | F · Tax | $156.22 | −1,936 | 22,647 | -8% | $302K | ||
| Sep 15, 202617:07 | Sep 11, 2026 | NBIX | Chief Scientific Officer | A · Grant | — | +3,587 | 24,583 | +17% | — | ||
| Sep 15, 202617:06 | Sep 11, 2026 | NBIX | Chief Legal Officer | F · Tax | $156.22 | −2,419 | 56,793 | -4% | $378K | ||
| Sep 15, 202617:06 | Sep 11, 2026 | NBIX | Chief Legal Officer | A · Grant | — | +4,483 | 59,212 | +8% | — | ||
| Sep 15, 202617:05 | Sep 11, 2026 | NBIX | Chief Medical Officer | F · Tax | $156.22 | −2,112 | 3,281 | -39% | $330K | ||
| Sep 15, 202617:05 | Sep 11, 2026 | NBIX | Chief Medical Officer | A · Grant | — | +3,914 | 5,393 | +265% | — | ||
| Sep 15, 202617:05 | Sep 11, 2026 | NBIX | Director | F · Tax | $156.22 | −7,839 | 517,797 | -1% | $1.2M | ||
| Sep 15, 202617:05 | Sep 11, 2026 | NBIX | Director | A · Grant | — | +14,343 | 525,636 | +3% | — | ||
| Sep 15, 202617:05 | Sep 11, 2026 | NBIX | Chief Executive Officer, Director | F · Tax | $156.22 | −4,380 | 154,728 | -3% | $684K | ||
| Sep 15, 202617:05 | Sep 11, 2026 | NBIX | Chief Executive Officer, Director | A · Grant | — | +8,117 | 155,722 | +5% | — | ||
| Sep 15, 202617:04 | Sep 11, 2026 | NBIX | Chief Regulatory Officer | F · Tax | $156.22 | −2,419 | 18,289 | -12% | $378K | ||
| Sep 15, 202617:04 | Sep 11, 2026 | NBIX | Chief Regulatory Officer | A · Grant | — | +4,483 | 20,708 | +28% | — | ||
| Sep 15, 202617:03 | Sep 11, 2026 | NBIX | Chief Human Resources Officer | F · Tax | $156.22 | −1,936 | 24,025 | -7% | $302K | ||
| Sep 15, 202617:03 | Sep 11, 2026 | NBIX | Chief Human Resources Officer | A · Grant | — | +3,587 | 25,961 | +16% | — | ||
| Sep 15, 202617:03 | Sep 14, 2026 | NBIX | Chief Corp. Affairs Officer | S · Sell10b5-1 | $157.45 | −826 | 8,722 | -9% | −$130K | ||
| Sep 15, 202617:03 | Sep 11, 2026 | NBIX | Chief Corp. Affairs Officer | F · Tax10b5-1 | $156.22 | −1,936 | 9,548 | -17% | $302K | ||
| Sep 15, 202617:03 | Sep 11, 2026 | NBIX | Chief Corp. Affairs Officer | A · Grant10b5-1 | — | +3,587 | 11,484 | +45% | — | ||
| Sep 15, 202617:02 | Sep 11, 2026 | NBIX | Chief Commercial Officer | F · Tax | $156.22 | −3,386 | 67,297 | -5% | $529K | ||
| Sep 15, 202617:02 | Sep 11, 2026 | NBIX | Chief Commercial Officer | A · Grant | — | +6,275 | 70,683 | +10% | — | ||
| Sep 15, 202617:02 | Sep 14, 2026 | NBIX | Chief Financial Officer | S · Sell10b5-1 | $157.20 | −2,311 | 42,808 | -5% | −$363K | ||
| Sep 15, 202617:02 | Sep 11, 2026 | NBIX | Chief Financial Officer | F · Tax10b5-1 | $156.22 | −2,709 | 45,119 | -6% | $423K | ||
| Sep 15, 202617:02 | Sep 11, 2026 | NBIX | Chief Financial Officer | A · Grant10b5-1 | — | +5,020 | 47,828 | +12% | — | ||
| Sep 10, 202620:29 | Sep 9, 2026 | NBIX | Chief Commercial Officer | S · Sell10b5-1 | $154.61 | −2,154 | 64,408 | -3% | −$333K | ||
| Sep 10, 202620:29 | Sep 9, 2026 | NBIX | Chief Commercial Officer | M · Exercise10b5-1 | $43.24 | +3,194 | 66,562 | +5% | $138K | ||
| Sep 3, 202621:39 | Sep 2, 2026 | NBIX | Director | G · Gift | — | −1,000 | 14,860 | -6% | — | ||
| Aug 5, 202617:35 | Aug 4, 2026 | NBIX | Chief Scientific Officer | G · Gift | — | −2,409 | 20,996 | -10% | — |